https://novapharmanews.com/eu/news/european-research-revolution-day-1-highlights 2026-05-05T05:17:29.510Z hourly 0.9 NovaPharmaNews en-GB 2026-05-05T04:03:38.738Z European Research Revolution: Day 1 Highlights https://novapharmanews.com/uploads/articles/european-research-revolution-day-1-highlights.webp European Research Revolution: Day 1 Highlights https://novapharmanews.com/eu/news/raps-euro-convergence-regulatory-updates-day-1 2026-05-05T04:33:33.677Z hourly 0.9 NovaPharmaNews en-GB 2026-05-05T04:02:44.472Z RAPS Euro Convergence: Key Regulatory Updates - Day 1 https://novapharmanews.com/uploads/articles/raps-euro-convergence-regulatory-updates-day-1.webp RAPS Euro Convergence: Key Regulatory Updates - Day 1 https://novapharmanews.com/apac/news/cryoport-q1-2026-financial-results-clinical-trials-cell-gene-therapy 2026-05-05T05:19:20.045Z hourly 0.9 NovaPharmaNews en 2026-05-05T03:05:52.376Z Cryoport Q1 2026 Results: Revenue Jumps 26% Supporting Record 766 Clinical Trials and 21 Commercial Cell Gene Therapies https://novapharmanews.com/uploads/articles/cryoport-q1-2026-financial-results-clinical-trials-cell-gene-therapy.webp Cryoport Q1 2026 Results: Revenue Jumps 26% Supporting Record 766 Clinical Trials and 21 Commercial Cell Gene Therapies https://novapharmanews.com/apac/news/ascidian-acdn-01-stellar-trial-stargardt-disease-dose-escalation-complete 2026-05-05T05:19:22.881Z hourly 0.9 NovaPharmaNews en 2026-05-05T03:05:16.660Z Ascidian Therapeutics Completes ACDN-01 Dose Escalation in STELLAR Phase 1/2 Trial for Stargardt Disease https://novapharmanews.com/uploads/articles/ascidian-acdn-01-stellar-trial-stargardt-disease-dose-escalation-complete.webp Ascidian Therapeutics Completes ACDN-01 Dose Escalation in STELLAR Phase 1/2 Trial for Stargardt Disease https://novapharmanews.com/apac/news/quiver-bioscience-nih-heal-grant-qv-2421-chronic-pain-trials 2026-05-05T05:17:20.375Z hourly 0.9 NovaPharmaNews en 2026-05-05T03:04:49.478Z Quiver Bioscience Receives NIH HEAL Initiative Grant for QV-2421 Chronic Pain Therapy Clinical Trials https://novapharmanews.com/uploads/articles/quiver-bioscience-nih-heal-grant-qv-2421-chronic-pain-trials.webp Quiver Bioscience Receives NIH HEAL Initiative Grant for QV-2421 Chronic Pain Therapy Clinical Trials https://novapharmanews.com/apac/news/lunai-bioworks-20-million-cns-drug-delivery-alzheimer-treatment 2026-05-05T05:19:24.333Z hourly 0.9 NovaPharmaNews en 2026-05-05T03:04:41.306Z Lunai Bioworks Raises $20 Million to Acquire CNS Drug Delivery Technology for Alzheimer's Treatment https://novapharmanews.com/uploads/articles/lunai-bioworks-20-million-cns-drug-delivery-alzheimer-treatment.webp Lunai Bioworks Raises $20 Million to Acquire CNS Drug Delivery Technology for Alzheimer's Treatment https://novapharmanews.com/apac/news/stryker-australia-tga-approval-temporomandibular-joint-prosthesis 2026-05-05T04:25:06.395Z hourly 0.9 NovaPharmaNews en 2026-05-05T03:04:04.502Z Stryker Australia Receives TGA Approval for Total Temporomandibular Joint Prosthesis https://novapharmanews.com/uploads/articles/stryker-australia-tga-approval-temporomandibular-joint-prosthesis.webp Stryker Australia Receives TGA Approval for Total Temporomandibular Joint Prosthesis https://novapharmanews.com/apac/news/tga-section-41hd-medical-device-emergency-import-approvals-australia 2026-05-05T05:19:15.319Z hourly 0.9 NovaPharmaNews en 2026-05-05T03:03:44.122Z Australia's TGA Section 41HD Emergency Medical Device Import Approvals: Complete Guide for Healthcare Providers https://novapharmanews.com/uploads/articles/tga-section-41hd-medical-device-emergency-import-approvals-australia.webp Australia's TGA Section 41HD Emergency Medical Device Import Approvals: Complete Guide for Healthcare Providers https://novapharmanews.com/eu/news/biotheryx-btx-9341-phase-1a-results-esmo-breast-cancer-congress-2026 2026-05-05T05:19:27.466Z hourly 0.9 NovaPharmaNews en-GB 2026-05-05T03:03:23.007Z Biotheryx BTX-9341 Phase 1A Results to Be Presented at ESMO Breast Cancer Congress 2026 https://novapharmanews.com/uploads/articles/biotheryx-btx-9341-phase-1a-results-esmo-breast-cancer-congress-2026.webp Biotheryx BTX-9341 Phase 1A Results to Be Presented at ESMO Breast Cancer Congress 2026 https://novapharmanews.com/us/news/palvella-qtorin-rapamycin-phase-2-trial-angiokeratomas 2026-05-05T05:17:32.143Z hourly 0.9 NovaPharmaNews en-US 2026-05-05T03:03:01.906Z Palvella Therapeutics Begins Phase 2 Trial of QTORIN Rapamycin for Rare Angiokeratomas https://novapharmanews.com/uploads/articles/palvella-qtorin-rapamycin-phase-2-trial-angiokeratomas.webp Palvella Therapeutics Begins Phase 2 Trial of QTORIN Rapamycin for Rare Angiokeratomas https://novapharmanews.com/us/news/neurocrine-biosciences-nbip-2118-phase-1-obesity-trial 2026-05-05T05:19:22.152Z hourly 0.9 NovaPharmaNews en-US 2026-05-05T03:02:33.709Z Neurocrine Biosciences Begins Phase 1 Trial of NBIP-2118 for Obesity Treatment https://novapharmanews.com/uploads/articles/neurocrine-biosciences-nbip-2118-phase-1-obesity-trial.webp Neurocrine Biosciences Begins Phase 1 Trial of NBIP-2118 for Obesity Treatment https://novapharmanews.com/us/news/caplyta-lumateperone-tops-adjunctive-depression-treatments-meta-analysis 2026-05-05T05:19:29.142Z hourly 0.9 NovaPharmaNews en-US 2026-05-05T03:02:13.206Z CAPLYTA (Lumateperone) Ranks Highest Among FDA-Approved Adjunctive Depression Treatments in Network Meta-Analysis https://novapharmanews.com/uploads/articles/caplyta-lumateperone-tops-adjunctive-depression-treatments-meta-analysis.webp CAPLYTA (Lumateperone) Ranks Highest Among FDA-Approved Adjunctive Depression Treatments in Network Meta-Analysis https://novapharmanews.com/us/news/cellenkos-fda-clearance-ck0802-phase-2a-trial-steroid-refractory-gvhd 2026-05-05T05:19:15.132Z hourly 0.9 NovaPharmaNews en-US 2026-05-05T03:01:37.465Z Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD https://novapharmanews.com/uploads/articles/cellenkos-fda-clearance-ck0802-phase-2a-trial-steroid-refractory-gvhd.webp Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD https://novapharmanews.com/us/news/cellenkos-fda-clearance-ck0802-phase-1b-2a-trial-steroid-refractory-gvhd 2026-05-05T05:17:29.933Z hourly 0.9 NovaPharmaNews en-US 2026-05-05T03:01:11.768Z Cellenkos Receives FDA Clearance for CK0802 Phase 1b/2a Trial in Steroid-Refractory GVHD https://novapharmanews.com/uploads/articles/cellenkos-fda-clearance-ck0802-phase-1b-2a-trial-steroid-refractory-gvhd.webp Cellenkos Receives FDA Clearance for CK0802 Phase 1b/2a Trial in Steroid-Refractory GVHD https://novapharmanews.com/us/news/fda-approves-guardant360-cdx-veppanu-breast-cancer-diagnostic 2026-05-05T05:19:17.417Z hourly 0.9 NovaPharmaNews en-US 2026-05-05T03:00:51.642Z FDA Approves Guardant360 CDx Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer https://novapharmanews.com/uploads/articles/fda-approves-guardant360-cdx-veppanu-breast-cancer-diagnostic.webp FDA Approves Guardant360 CDx Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer https://novapharmanews.com/us/news/opus-genetics-opgx-lca5-fda-rare-disease-evidence-program 2026-05-05T05:17:33.854Z hourly 0.9 NovaPharmaNews en-US 2026-05-05T03:00:20.522Z Opus Genetics' OPGx-LCA5 Gene Therapy Accepted Into FDA's Rare Disease Evidence Program https://novapharmanews.com/uploads/articles/opus-genetics-opgx-lca5-fda-rare-disease-evidence-program.webp Opus Genetics' OPGx-LCA5 Gene Therapy Accepted Into FDA's Rare Disease Evidence Program https://novapharmanews.com/eu/news/raps-euro-convergence-2026-day-1-roundup 2026-05-05T05:19:16.911Z hourly 0.9 NovaPharmaNews en-GB 2026-05-05T00:04:44.850Z RAPS Euro Convergence 2026: Regulatory News - Day 1 Roundup https://novapharmanews.com/uploads/articles/raps-euro-convergence-2026-day-1-roundup.webp RAPS Euro Convergence 2026: Regulatory News - Day 1 Roundup https://novapharmanews.com/eu/news/heart-failure-2026-vutrisiran-data-european-pharma-news 2026-05-05T05:17:18.488Z hourly 0.9 NovaPharmaNews en-GB 2026-05-05T00:03:25.154Z Heart Failure 2026: Vutrisiran Data & European Pharma News https://novapharmanews.com/uploads/articles/heart-failure-2026-vutrisiran-data-european-pharma-news.webp Heart Failure 2026: Vutrisiran Data & European Pharma News https://novapharmanews.com/apac/news/telix-tlx250-px-zircaix-kidney-cancer-diagnosis-phase-3-zircon 2026-05-05T05:17:14.918Z hourly 0.9 NovaPharmaNews en 2026-05-04T23:25:23.249Z Telix Pharmaceuticals' TLX250-Px Shows Promise for Diagnosing Multiple Kidney Cancer Types Beyond Clear Cell RCC https://novapharmanews.com/uploads/articles/telix-tlx250-px-zircaix-kidney-cancer-diagnosis-phase-3-zircon.webp Telix Pharmaceuticals' TLX250-Px Shows Promise for Diagnosing Multiple Kidney Cancer Types Beyond Clear Cell RCC https://novapharmanews.com/apac/news/arrowhead-pharmaceuticals-redemplo-plozasiran-tga-approval-australia-fcs 2026-05-05T05:17:23.577Z hourly 0.9 NovaPharmaNews en 2026-05-04T23:24:45.988Z Arrowhead Pharmaceuticals Receives TGA Approval for REDEMPLO (Plozasiran) in Australia for Rare Metabolic Disorder https://novapharmanews.com/uploads/articles/arrowhead-pharmaceuticals-redemplo-plozasiran-tga-approval-australia-fcs.webp Arrowhead Pharmaceuticals Receives TGA Approval for REDEMPLO (Plozasiran) in Australia for Rare Metabolic Disorder https://novapharmanews.com/apac/news/mifepristone-access-supreme-court-hold-planned-parenthood-5th-circuit 2026-05-05T05:19:17.908Z hourly 0.9 NovaPharmaNews en 2026-05-04T23:24:15.591Z Mifepristone Access Continues Under Supreme Court Hold as Planned Parenthood Responds to 5th Circuit Ruling https://novapharmanews.com/uploads/articles/mifepristone-access-supreme-court-hold-planned-parenthood-5th-circuit.webp Mifepristone Access Continues Under Supreme Court Hold as Planned Parenthood Responds to 5th Circuit Ruling https://novapharmanews.com/eu/news/cvrx-benefit-hf-trial-barostim-heart-failure-first-patient 2026-05-05T05:19:28.563Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T23:23:47.606Z CVRx Enrolls First Patient in BENEFIT-HF Heart Failure Trial Testing Barostim Device https://novapharmanews.com/uploads/articles/cvrx-benefit-hf-trial-barostim-heart-failure-first-patient.webp CVRx Enrolls First Patient in BENEFIT-HF Heart Failure Trial Testing Barostim Device https://novapharmanews.com/eu/news/agenus-q1-2026-financial-report-botensilimab-balstilimab-update 2026-05-05T05:17:17.739Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T23:23:26.670Z Agenus Announces Q1 2026 Financial Report Date for Botensilimab and Balstilimab Cancer Programs https://novapharmanews.com/uploads/articles/agenus-q1-2026-financial-report-botensilimab-balstilimab-update.webp Agenus Announces Q1 2026 Financial Report Date for Botensilimab and Balstilimab Cancer Programs https://novapharmanews.com/eu/news/oncolytics-biotech-pelareorep-colorectal-cancer-durable-responses 2026-05-05T05:17:22.893Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T23:23:01.552Z Oncolytics Biotech Reports Durable Responses with Pelareorep in RAS-Mutant Colorectal Cancer Trial https://novapharmanews.com/uploads/articles/oncolytics-biotech-pelareorep-colorectal-cancer-durable-responses.webp Oncolytics Biotech Reports Durable Responses with Pelareorep in RAS-Mutant Colorectal Cancer Trial https://novapharmanews.com/eu/news/crispr-therapeutics-q1-2026-casgevy-global-approval 2026-05-05T05:19:25.777Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T23:22:35.783Z CRISPR Therapeutics Reports Q1 2026 Results as CASGEVY Gene Therapy Gains Global Regulatory Approval https://novapharmanews.com/uploads/articles/crispr-therapeutics-q1-2026-casgevy-global-approval.webp CRISPR Therapeutics Reports Q1 2026 Results as CASGEVY Gene Therapy Gains Global Regulatory Approval https://novapharmanews.com/us/news/clene-cnm-au8-fda-accelerated-approval-als-treatment-2024 2026-05-05T05:19:18.930Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T23:22:10.529Z Clene Receives FDA Green Light for CNM-Au8 Accelerated Approval Pathway in ALS Treatment https://novapharmanews.com/uploads/articles/clene-cnm-au8-fda-accelerated-approval-als-treatment-2024.webp Clene Receives FDA Green Light for CNM-Au8 Accelerated Approval Pathway in ALS Treatment https://novapharmanews.com/us/news/alpha-tau-alpha-dart-100-percent-disease-control-pancreatic-cancer-ddw-2026 2026-05-05T05:17:22.227Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T23:21:46.096Z Alpha Tau's Alpha DaRT Achieves 100% Local Disease Control in Pancreatic Cancer Trials at DDW 2026 https://novapharmanews.com/uploads/articles/alpha-tau-alpha-dart-100-percent-disease-control-pancreatic-cancer-ddw-2026.webp Alpha Tau's Alpha DaRT Achieves 100% Local Disease Control in Pancreatic Cancer Trials at DDW 2026 https://novapharmanews.com/us/news/takeda-tak-881-positive-phase-2-3-results-primary-immunodeficiency-disease 2026-05-05T05:19:21.408Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T23:21:19.488Z Takeda's TAK-881 Shows Positive Phase 2/3 Results for Primary Immunodeficiency Disease Treatment https://novapharmanews.com/uploads/articles/takeda-tak-881-positive-phase-2-3-results-primary-immunodeficiency-disease.webp Takeda's TAK-881 Shows Positive Phase 2/3 Results for Primary Immunodeficiency Disease Treatment https://novapharmanews.com/us/news/accord-healthcare-relaunches-tadalafil-tablets-generic-ed-treatment 2026-05-05T05:19:20.871Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T23:20:58.919Z Accord Healthcare Relaunches Tadalafil Tablets in Multiple Dosage Strengths, Expanding Generic ED Treatment Access https://novapharmanews.com/uploads/articles/accord-healthcare-relaunches-tadalafil-tablets-generic-ed-treatment.webp Accord Healthcare Relaunches Tadalafil Tablets in Multiple Dosage Strengths, Expanding Generic ED Treatment Access https://novapharmanews.com/us/news/inspiremd-fda-approval-switchguard-neuro-protection-cguardians-iii-trial 2026-05-05T04:05:15.496Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T23:20:31.756Z InspireMD Receives FDA Approval for SwitchGuard Neuro Protection System CGUARDIANS III Pivotal Trial https://novapharmanews.com/uploads/articles/inspiremd-fda-approval-switchguard-neuro-protection-cguardians-iii-trial.webp InspireMD Receives FDA Approval for SwitchGuard Neuro Protection System CGUARDIANS III Pivotal Trial https://novapharmanews.com/apac/news/xtalpi-pep08-prmt5-inhibitor-phase-1-cancer-trial-enrollment 2026-05-05T05:17:16.655Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:17:29.885Z XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment https://novapharmanews.com/uploads/articles/xtalpi-pep08-prmt5-inhibitor-phase-1-cancer-trial-enrollment.webp XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment https://novapharmanews.com/apac/news/spontan-phase-ii-data-10-minute-onset-fda-requirements-erectile-dysfunction 2026-05-05T00:19:50.990Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:17:19.213Z SPONTAN Phase II Data Shows 10-Minute Onset Time, Meets FDA Requirements for Erectile Dysfunction Treatment https://novapharmanews.com/uploads/articles/spontan-phase-ii-data-10-minute-onset-fda-requirements-erectile-dysfunction.webp SPONTAN Phase II Data Shows 10-Minute Onset Time, Meets FDA Requirements for Erectile Dysfunction Treatment https://novapharmanews.com/apac/news/ironwood-pharmaceuticals-short-bowel-syndrome-tpn-survey-ddw-2026 2026-05-05T05:19:26.225Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:16:57.513Z Ironwood Pharmaceuticals Survey Reveals Critical Gaps in Short Bowel Syndrome TPN Treatment at DDW 2026 https://novapharmanews.com/uploads/articles/ironwood-pharmaceuticals-short-bowel-syndrome-tpn-survey-ddw-2026.webp Ironwood Pharmaceuticals Survey Reveals Critical Gaps in Short Bowel Syndrome TPN Treatment at DDW 2026 https://novapharmanews.com/apac/news/edwards-lifesciences-resilia-tissue-10-year-commence-trial-results 2026-05-05T04:39:01.281Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:16:22.727Z Edwards Lifesciences RESILIA Tissue Shows 10-Year Durability in COMMENCE Aortic Trial Results https://novapharmanews.com/uploads/articles/edwards-lifesciences-resilia-tissue-10-year-commence-trial-results.webp Edwards Lifesciences RESILIA Tissue Shows 10-Year Durability in COMMENCE Aortic Trial Results https://novapharmanews.com/apac/news/novo-nordisk-wegovy-china-launch-eli-lilly-obesity-market 2026-05-05T05:19:20.058Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:16:20.835Z Novo Nordisk Launches Wegovy in China Before Eli Lilly, Capturing World's Largest Obesity Market https://novapharmanews.com/uploads/articles/novo-nordisk-wegovy-china-launch-eli-lilly-obesity-market.webp Novo Nordisk Launches Wegovy in China Before Eli Lilly, Capturing World's Largest Obesity Market https://novapharmanews.com/apac/news/arrowhead-pharmaceuticals-tga-approval-redemplo-plozasiran-australia-fcs 2026-05-05T05:17:14.322Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:15:28.387Z Arrowhead Pharmaceuticals Receives TGA Approval for REDEMPLO (Plozasiran) in Australia for Rare Genetic Disorder https://novapharmanews.com/uploads/articles/arrowhead-pharmaceuticals-tga-approval-redemplo-plozasiran-australia-fcs.webp Arrowhead Pharmaceuticals Receives TGA Approval for REDEMPLO (Plozasiran) in Australia for Rare Genetic Disorder https://novapharmanews.com/apac/news/biomarin-palynziq-fda-approval-adolescent-pku-patients 2026-05-05T05:19:16.707Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:15:04.650Z BioMarin's PALYNZIQ Receives FDA Approval for Adolescent PKU Patients 12 and Older https://novapharmanews.com/uploads/articles/biomarin-palynziq-fda-approval-adolescent-pku-patients.webp BioMarin's PALYNZIQ Receives FDA Approval for Adolescent PKU Patients 12 and Older https://novapharmanews.com/apac/news/rois-us-expansion-global-cdmo-fda-approval-injectable-manufacturing 2026-05-05T05:17:23.238Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:14:55.579Z ROIS Expands to US Market as Global CDMO with FDA Approval for Injectable Drug Manufacturing https://novapharmanews.com/uploads/articles/rois-us-expansion-global-cdmo-fda-approval-injectable-manufacturing.webp ROIS Expands to US Market as Global CDMO with FDA Approval for Injectable Drug Manufacturing https://novapharmanews.com/apac/news/fda-approves-travere-filspari-fsgs-treatment-adults-children 2026-05-05T05:19:56.201Z hourly 0.9 NovaPharmaNews en 2026-05-04T21:14:09.600Z FDA Approves Travere's FILSPARI for FSGS Treatment in Adults and Children 8+ https://novapharmanews.com/uploads/articles/fda-approves-travere-filspari-fsgs-treatment-adults-children.webp FDA Approves Travere's FILSPARI for FSGS Treatment in Adults and Children 8+ https://novapharmanews.com/eu/news/vanda-pharmaceuticals-nereus-tradipitant-motion-sickness-drug-launch 2026-05-04T23:08:37.503Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:14:01.328Z Vanda Pharmaceuticals Launches NEREUS (Tradipitant) - First New Motion Sickness Drug in 40+ Years Now Available https://novapharmanews.com/uploads/articles/vanda-pharmaceuticals-nereus-tradipitant-motion-sickness-drug-launch.webp Vanda Pharmaceuticals Launches NEREUS (Tradipitant) - First New Motion Sickness Drug in 40+ Years Now Available https://novapharmanews.com/eu/news/takeda-tak-881-phase-3-trial-primary-immunodeficiency-disease-results 2026-05-05T03:22:37.523Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:13:28.315Z Takeda's TAK-881 Meets Primary Endpoint in Phase 2/3 Trial for Primary Immunodeficiency Disease https://novapharmanews.com/uploads/articles/takeda-tak-881-phase-3-trial-primary-immunodeficiency-disease-results.webp Takeda's TAK-881 Meets Primary Endpoint in Phase 2/3 Trial for Primary Immunodeficiency Disease https://novapharmanews.com/eu/news/pulse-biosciences-atrial-fibrillation-treatment-100-percent-success-rate-2026 2026-05-05T05:17:22.551Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:13:07.806Z Pulse Biosciences Reports 100% Success Rate in Atrial Fibrillation Treatment Trial at Heart Rhythm 2026 https://novapharmanews.com/uploads/articles/pulse-biosciences-atrial-fibrillation-treatment-100-percent-success-rate-2026.webp Pulse Biosciences Reports 100% Success Rate in Atrial Fibrillation Treatment Trial at Heart Rhythm 2026 https://novapharmanews.com/eu/news/sq-innovation-lasix-onyu-subcut-hf-ii-trial-results-heart-failure-2026 2026-05-05T05:19:18.262Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:12:47.033Z SQ Innovation's Lasix ONYU Subcutaneous Heart Failure Trial Results to Be Presented at Heart Failure 2026 https://novapharmanews.com/uploads/articles/sq-innovation-lasix-onyu-subcut-hf-ii-trial-results-heart-failure-2026.webp SQ Innovation's Lasix ONYU Subcutaneous Heart Failure Trial Results to Be Presented at Heart Failure 2026 https://novapharmanews.com/eu/news/krystal-biotech-q1-2026-results-vyjuvek-expansion-registrational-studies 2026-05-05T05:17:34.513Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:12:24.994Z Krystal Biotech Reports Strong Q1 2026 Results with VYJUVEK Global Expansion and Two Registrational Studies Pending https://novapharmanews.com/uploads/articles/krystal-biotech-q1-2026-results-vyjuvek-expansion-registrational-studies.webp Krystal Biotech Reports Strong Q1 2026 Results with VYJUVEK Global Expansion and Two Registrational Studies Pending https://novapharmanews.com/eu/news/acurx-dna-pol-iiic-inhibitors-microbiome-preservation-mrsa-escmid-2026 2026-05-05T05:19:22.986Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:12:13.267Z Acurx DNA pol IIIC Inhibitors Show Gut Microbiome Preservation in MRSA Treatment Study at ESCMID Global 2026 https://novapharmanews.com/uploads/articles/acurx-dna-pol-iiic-inhibitors-microbiome-preservation-mrsa-escmid-2026.webp Acurx DNA pol IIIC Inhibitors Show Gut Microbiome Preservation in MRSA Treatment Study at ESCMID Global 2026 https://novapharmanews.com/eu/news/biocryst-navenibart-european-licensing-deal-neopharmed-gentili 2026-05-05T05:20:18.741Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:11:34.136Z BioCryst Secures $70M Upfront in European Licensing Deal for Navenibart Hereditary Angioedema Treatment https://novapharmanews.com/uploads/articles/biocryst-navenibart-european-licensing-deal-neopharmed-gentili.webp BioCryst Secures $70M Upfront in European Licensing Deal for Navenibart Hereditary Angioedema Treatment https://novapharmanews.com/eu/news/biosimulation-market-11-billion-2031-drug-development 2026-05-05T05:19:11.429Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:11:01.029Z Biosimulation Market to Reach $11.3 Billion by 2031 as Pharmaceutical Companies Accelerate Digital Drug Development https://novapharmanews.com/uploads/articles/biosimulation-market-11-billion-2031-drug-development.webp Biosimulation Market to Reach $11.3 Billion by 2031 as Pharmaceutical Companies Accelerate Digital Drug Development https://novapharmanews.com/eu/news/grin-therapeutics-phase-3-beeline-study-radiprodil-europe-grin-ndd 2026-05-05T05:17:11.733Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:10:50.384Z GRIN Therapeutics Expands Phase 3 Beeline Study for Radiprodil to Europe for GRIN-NDD Treatment https://novapharmanews.com/uploads/articles/grin-therapeutics-phase-3-beeline-study-radiprodil-europe-grin-ndd.webp GRIN Therapeutics Expands Phase 3 Beeline Study for Radiprodil to Europe for GRIN-NDD Treatment https://novapharmanews.com/eu/news/fda-approves-langlara-biosimilar-lantus-insulin-lannett-company 2026-05-05T04:36:26.114Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:10:15.364Z FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Receives Key Diabetes Drug Approval https://novapharmanews.com/uploads/articles/fda-approves-langlara-biosimilar-lantus-insulin-lannett-company.webp FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Receives Key Diabetes Drug Approval https://novapharmanews.com/eu/news/vertex-casgevy-gene-therapy-global-expansion-q1-2026-results 2026-05-05T05:17:18.360Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:09:44.026Z Vertex CASGEVY Gene Therapy Reaches 60,000+ Eligible Patients Across 10 Countries as Q1 2026 Results Show Global Expansion https://novapharmanews.com/uploads/articles/vertex-casgevy-gene-therapy-global-expansion-q1-2026-results.webp Vertex CASGEVY Gene Therapy Reaches 60,000+ Eligible Patients Across 10 Countries as Q1 2026 Results Show Global Expansion https://novapharmanews.com/eu/news/oncolytics-biotech-pelareorep-durable-responses-ras-mutant-colorectal-cancer 2026-05-05T05:19:22.198Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:09:14.671Z Oncolytics Biotech Pelareorep Shows Durable Responses in RAS-Mutant Colorectal Cancer Trial https://novapharmanews.com/uploads/articles/oncolytics-biotech-pelareorep-durable-responses-ras-mutant-colorectal-cancer.webp Oncolytics Biotech Pelareorep Shows Durable Responses in RAS-Mutant Colorectal Cancer Trial https://novapharmanews.com/eu/news/nuvation-bio-ibtrozi-q1-2026-revenue-ros1-nsclc 2026-05-05T05:17:12.833Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T21:09:05.890Z Nuvation Bio's IBTROZI Generates $18.5M Revenue in Q1 2026, Shows Strong First-Line Adoption in ROS1+ NSCLC https://novapharmanews.com/uploads/articles/nuvation-bio-ibtrozi-q1-2026-revenue-ros1-nsclc.webp Nuvation Bio's IBTROZI Generates $18.5M Revenue in Q1 2026, Shows Strong First-Line Adoption in ROS1+ NSCLC https://novapharmanews.com/us/news/crispr-therapeutics-casgevy-global-approvals-60000-patients 2026-05-05T05:17:14.249Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:08:28.176Z CRISPR Therapeutics' CASGEVY Reaches 60,000+ Eligible Patients Across 10 Countries Following Global Approvals https://novapharmanews.com/uploads/articles/crispr-therapeutics-casgevy-global-approvals-60000-patients.webp CRISPR Therapeutics' CASGEVY Reaches 60,000+ Eligible Patients Across 10 Countries Following Global Approvals https://novapharmanews.com/us/news/clene-cnm-au8-fda-accelerated-approval-pathway-als-treatment 2026-05-05T04:22:01.597Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:07:56.203Z Clene's CNM-Au8 Gets FDA Green Light for Accelerated Approval Pathway in ALS Treatment https://novapharmanews.com/uploads/articles/clene-cnm-au8-fda-accelerated-approval-pathway-als-treatment.webp Clene's CNM-Au8 Gets FDA Green Light for Accelerated Approval Pathway in ALS Treatment https://novapharmanews.com/us/news/atossa-therapeutics-fda-rare-pediatric-disease-designation-z-endoxifen-mccune-albright-syndrome 2026-05-05T05:18:55.708Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:07:47.490Z Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen in McCune-Albright Syndrome https://novapharmanews.com/uploads/articles/atossa-therapeutics-fda-rare-pediatric-disease-designation-z-endoxifen-mccune-albright-syndrome.webp Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen in McCune-Albright Syndrome https://novapharmanews.com/us/news/mbiota-elemental-ibs-treatment-ddw-2026-clinical-trial 2026-05-05T03:10:08.385Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:07:06.345Z mBIOTA Elemental Diet Shows Promise for IBS Treatment in New Clinical Trial Data Presented at DDW 2026 https://novapharmanews.com/uploads/articles/mbiota-elemental-ibs-treatment-ddw-2026-clinical-trial.webp mBIOTA Elemental Diet Shows Promise for IBS Treatment in New Clinical Trial Data Presented at DDW 2026 https://novapharmanews.com/us/news/novartis-fabhalta-health-canada-approval-c3g-treatment 2026-05-05T05:19:14.218Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:06:46.384Z Novartis Receives Health Canada Approval for Fabhalta Oral Treatment for C3G Patients https://novapharmanews.com/uploads/articles/novartis-fabhalta-health-canada-approval-c3g-treatment.webp Novartis Receives Health Canada Approval for Fabhalta Oral Treatment for C3G Patients https://novapharmanews.com/us/news/asco-2026-cellectar-waldenstrom-macroglobulinemia 2026-05-04T23:21:45.738Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:06:45.729Z ASCO 2026: Cellectar's Waldenström Macroglobulinemia Data https://novapharmanews.com/uploads/articles/asco-2026-cellectar-waldenstrom-macroglobulinemia.webp ASCO 2026: Cellectar's Waldenström Macroglobulinemia Data https://novapharmanews.com/us/news/alpha-tau-alpha-dart-pancreatic-cancer-trials-ddw-2026 2026-05-05T04:39:07.283Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:06:20.926Z Alpha Tau's Alpha DaRT Achieves 100% Local Disease Control in Pancreatic Cancer Trials at DDW 2026 https://novapharmanews.com/uploads/articles/alpha-tau-alpha-dart-pancreatic-cancer-trials-ddw-2026.webp Alpha Tau's Alpha DaRT Achieves 100% Local Disease Control in Pancreatic Cancer Trials at DDW 2026 https://novapharmanews.com/us/news/cytokinetics-aficamten-phase-3-trial-results-non-obstructive-hypertrophic-cardiomyopathy-may-2026 2026-05-05T04:49:11.668Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:05:49.827Z Cytokinetics to Report Aficamten Phase 3 Trial Results for Non-Obstructive Hypertrophic Cardiomyopathy May 5, 2026 https://novapharmanews.com/uploads/articles/cytokinetics-aficamten-phase-3-trial-results-non-obstructive-hypertrophic-cardiomyopathy-may-2026.webp Cytokinetics to Report Aficamten Phase 3 Trial Results for Non-Obstructive Hypertrophic Cardiomyopathy May 5, 2026 https://novapharmanews.com/us/news/inflarx-izicopan-reactive-metabolite-liver-safety-study 2026-05-04T23:12:56.461Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:05:22.655Z InflaRx Izicopan Shows Low Reactive Metabolite Formation in Liver Safety Study https://novapharmanews.com/uploads/articles/inflarx-izicopan-reactive-metabolite-liver-safety-study.webp InflaRx Izicopan Shows Low Reactive Metabolite Formation in Liver Safety Study https://novapharmanews.com/us/news/macrogenics-expands-zynyz-royalty-agreement-sagard-healthcare 2026-05-04T23:15:01.489Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:05:13.838Z MacroGenics Expands ZYNYZ Royalty Agreement with Sagard Healthcare Partners for Cancer Drug https://novapharmanews.com/uploads/articles/macrogenics-expands-zynyz-royalty-agreement-sagard-healthcare.webp MacroGenics Expands ZYNYZ Royalty Agreement with Sagard Healthcare Partners for Cancer Drug https://novapharmanews.com/us/news/akebia-vadadustat-mortality-reduction-kidney-disease-jasn-study 2026-05-04T23:15:12.114Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:04:53.822Z Akebia Therapeutics Vadadustat Shows Significant Mortality Reduction in New Kidney Disease Analysis https://novapharmanews.com/uploads/articles/akebia-vadadustat-mortality-reduction-kidney-disease-jasn-study.webp Akebia Therapeutics Vadadustat Shows Significant Mortality Reduction in New Kidney Disease Analysis https://novapharmanews.com/us/news/inflarx-izicopan-favorable-liver-metabolism-safety-profile-2026 2026-05-05T05:19:19.298Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:04:22.004Z InflaRx Reports Favorable Safety Profile for Izicopan in Liver Metabolism Study https://novapharmanews.com/uploads/articles/inflarx-izicopan-favorable-liver-metabolism-safety-profile-2026.webp InflaRx Reports Favorable Safety Profile for Izicopan in Liver Metabolism Study https://novapharmanews.com/us/news/celcuity-gedatolisib-phase-3-viktoria-1-trial-pik3ca-mutant-cancer 2026-05-05T03:15:17.876Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:03:26.697Z Celcuity's Gedatolisib Meets Phase 3 Primary Endpoint in PIK3CA Mutant Cancer Trial https://novapharmanews.com/uploads/articles/celcuity-gedatolisib-phase-3-viktoria-1-trial-pik3ca-mutant-cancer.webp Celcuity's Gedatolisib Meets Phase 3 Primary Endpoint in PIK3CA Mutant Cancer Trial https://novapharmanews.com/us/news/fda-approves-langlara-interchangeable-biosimilar-lantus-insulin-lannett 2026-05-05T05:19:31.147Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:02:53.481Z FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Enters Diabetes Market https://novapharmanews.com/uploads/articles/fda-approves-langlara-interchangeable-biosimilar-lantus-insulin-lannett.webp FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Enters Diabetes Market https://novapharmanews.com/us/news/fda-approves-guardant360-cdx-companion-diagnostic-pfizer-veppanu-breast-cancer 2026-05-05T05:17:20.911Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:02:14.515Z FDA Approves Guardant360 CDx as Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer https://novapharmanews.com/uploads/articles/fda-approves-guardant360-cdx-companion-diagnostic-pfizer-veppanu-breast-cancer.webp FDA Approves Guardant360 CDx as Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer https://novapharmanews.com/us/news/fda-approves-incyte-jakafi-xr-extended-release-myelofibrosis 2026-05-05T03:16:43.171Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:01:50.675Z FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis and Blood Disorders https://novapharmanews.com/uploads/articles/fda-approves-incyte-jakafi-xr-extended-release-myelofibrosis.webp FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis and Blood Disorders https://novapharmanews.com/us/news/arvinas-veppanu-vepdegestrant-fda-approval-first-protac-drug-esr1-breast-cancer 2026-05-04T23:56:29.462Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T21:01:28.213Z Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer https://novapharmanews.com/uploads/articles/arvinas-veppanu-vepdegestrant-fda-approval-first-protac-drug-esr1-breast-cancer.webp Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer https://novapharmanews.com/us/news/excipient-world-conference-daily-roundup 2026-05-05T04:23:22.891Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T20:02:13.689Z Excipient World Conference: Key Highlights and Industry Trends https://novapharmanews.com/uploads/articles/excipient-world-conference-daily-roundup.webp Excipient World Conference: Key Highlights and Industry Trends https://novapharmanews.com/us/news/APHL-2026-annual-meeting-day-1-highlights 2026-05-05T05:17:15.336Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T16:00:35.928Z APHL 2026 Annual Meeting: Day 1 Highlights https://novapharmanews.com/uploads/articles/APHL-2026-annual-meeting-day-1-highlights.webp APHL 2026 Annual Meeting: Day 1 Highlights https://novapharmanews.com/us/news/aphl-2026-day-1-roundup 2026-05-05T05:17:28.710Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T12:00:31.547Z APHL 2026: Day 1 Highlights and Key Takeaways https://novapharmanews.com/uploads/articles/aphl-2026-day-1-roundup.webp APHL 2026: Day 1 Highlights and Key Takeaways https://novapharmanews.com/eu/news/swiss-biotech-day-daily-roundup 2026-05-05T05:17:20.096Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T08:01:51.242Z Swiss Biotech Day: Key Takeaways and Biotech Innovations https://novapharmanews.com/uploads/articles/swiss-biotech-day-daily-roundup.webp Swiss Biotech Day: Key Takeaways and Biotech Innovations https://novapharmanews.com/apac/news/fda-approves-auvelity-new-mdd-treatment 2026-05-05T05:19:26.970Z hourly 0.9 NovaPharmaNews en 2026-05-04T07:08:39.207Z FDA Approves Auvelity: A New Option for MDD https://novapharmanews.com/uploads/articles/fda-approves-auvelity-new-mdd-treatment.webp FDA Approves Auvelity: A New Option for MDD https://novapharmanews.com/apac/news/sun-pharma-organon-partnership-india 2026-05-04T23:12:03.904Z hourly 0.9 NovaPharmaNews en 2026-05-04T07:08:09.439Z Sun Pharma Organon Partnership to Expand Access to Key Medicines https://novapharmanews.com/uploads/articles/sun-pharma-organon-partnership-india.webp Sun Pharma Organon Partnership to Expand Access to Key Medicines https://novapharmanews.com/eu/news/fda-approves-auvelity-mdd-axsome-therapeutics 2026-05-05T05:17:30.247Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T07:05:54.602Z FDA Approves Auvelity for MDD: Axsome Therapeutics Scores Win https://novapharmanews.com/uploads/articles/fda-approves-auvelity-mdd-axsome-therapeutics.webp FDA Approves Auvelity for MDD: Axsome Therapeutics Scores Win https://novapharmanews.com/eu/news/purdue-pharma-shutdown-oxycontin-settlement 2026-05-05T05:06:13.790Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T07:04:18.946Z Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Operations https://novapharmanews.com/uploads/articles/purdue-pharma-shutdown-oxycontin-settlement.webp Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Operations https://novapharmanews.com/us/news/fda-approves-palazestrant-pfizer-arvinas-breast-cancer-drug 2026-05-05T05:19:32.358Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T07:02:27.732Z FDA Approves Palazestrant for Breast Cancer Amidst Data Concerns https://novapharmanews.com/uploads/articles/fda-approves-palazestrant-pfizer-arvinas-breast-cancer-drug.webp FDA Approves Palazestrant for Breast Cancer Amidst Data Concerns https://novapharmanews.com/eu/news/eular-2026-immutep-imp761-phase-1-preview 2026-05-04T23:21:39.726Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T05:03:13.771Z EULAR 2026: Immutep's IMP761 Phase I Data Preview https://novapharmanews.com/uploads/articles/eular-2026-immutep-imp761-phase-1-preview.webp EULAR 2026: Immutep's IMP761 Phase I Data Preview https://novapharmanews.com/us/news/thma-pharmacy-growth-priorities-2026 2026-05-04T23:34:47.254Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T05:02:27.663Z THMA Pharmacy Growth Priorities 2026: Key Insights for CPOs https://novapharmanews.com/uploads/articles/thma-pharmacy-growth-priorities-2026.webp THMA Pharmacy Growth Priorities 2026: Key Insights for CPOs https://novapharmanews.com/us/news/cphi-americas-2026-pharma-manufacturing-trends 2026-05-04T23:55:01.989Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T05:00:41.745Z CPhI Americas 2026: Pharma Manufacturing Trends in Philadelphia https://novapharmanews.com/uploads/articles/cphi-americas-2026-pharma-manufacturing-trends.webp CPhI Americas 2026: Pharma Manufacturing Trends in Philadelphia https://novapharmanews.com/us/news/ipec-americas-annual-meeting-daily-roundup 2026-05-05T05:19:25.054Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T04:02:03.608Z IPEC Americas Annual Meeting: Key Takeaways for Pharma Professionals https://novapharmanews.com/uploads/articles/ipec-americas-annual-meeting-daily-roundup.webp IPEC Americas Annual Meeting: Key Takeaways for Pharma Professionals https://novapharmanews.com/us/news/excipient-world-conference-day-1-highlights 2026-05-05T05:19:20.663Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T04:01:18.901Z Excipient World Conference: Day 1 Highlights https://novapharmanews.com/uploads/articles/excipient-world-conference-day-1-highlights.webp Excipient World Conference: Day 1 Highlights https://novapharmanews.com/us/news/aphl-2026-annual-day-1-roundup 2026-05-05T05:17:13.615Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T04:00:32.252Z APHL 2026 Annual: Day 1 Key Takeaways https://novapharmanews.com/uploads/articles/aphl-2026-annual-day-1-roundup.webp APHL 2026 Annual: Day 1 Key Takeaways https://novapharmanews.com/apac/news/ucb-acquires-candid-therapeutics-2-2-billion-t-cell-engager-autoimmune 2026-05-05T05:17:17.124Z hourly 0.9 NovaPharmaNews en 2026-05-04T03:03:42.696Z UCB Acquires Candid Therapeutics for $2.2 Billion, Expanding T-Cell Engager Platform for Autoimmune Diseases https://novapharmanews.com/uploads/articles/ucb-acquires-candid-therapeutics-2-2-billion-t-cell-engager-autoimmune.webp UCB Acquires Candid Therapeutics for $2.2 Billion, Expanding T-Cell Engager Platform for Autoimmune Diseases https://novapharmanews.com/eu/news/novelty-nobility-agc-biologics-bispecific-antibody-manufacturing-partnership 2026-05-04T23:16:36.178Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T03:02:58.961Z Novelty Nobility Expands AGC Biologics Partnership for Bispecific Antibody Manufacturing https://novapharmanews.com/uploads/articles/novelty-nobility-agc-biologics-bispecific-antibody-manufacturing-partnership.webp Novelty Nobility Expands AGC Biologics Partnership for Bispecific Antibody Manufacturing https://novapharmanews.com/eu/news/smartee-denti-technology-mandibular-repositioning-eas-congress-2026 2026-05-04T23:09:09.435Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T03:02:39.548Z Smartee Denti-Technology Advances Mandibular Repositioning Technology at European Aligner Society Congress 2026 https://novapharmanews.com/uploads/articles/smartee-denti-technology-mandibular-repositioning-eas-congress-2026.webp Smartee Denti-Technology Advances Mandibular Repositioning Technology at European Aligner Society Congress 2026 https://novapharmanews.com/us/news/xtalpi-pep08-prmt5-inhibitor-phase-1-cancer-trial-enrollment 2026-05-05T05:19:28.495Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:02:18.090Z XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment https://novapharmanews.com/uploads/articles/xtalpi-pep08-prmt5-inhibitor-phase-1-cancer-trial-enrollment.webp XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment https://novapharmanews.com/us/news/mirum-pharmaceuticals-vistas-volixibat-primary-sclerosing-cholangitis-results-may-2026 2026-05-05T04:40:47.968Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:01:56.836Z Mirum Pharmaceuticals VISTAS Study Results for Volixibat in Primary Sclerosing Cholangitis Due May 4, 2026 https://novapharmanews.com/uploads/articles/mirum-pharmaceuticals-vistas-volixibat-primary-sclerosing-cholangitis-results-may-2026.webp Mirum Pharmaceuticals VISTAS Study Results for Volixibat in Primary Sclerosing Cholangitis Due May 4, 2026 https://novapharmanews.com/us/news/everads-therapy-suprachoroidal-injector-clinical-data-ophthalmology-science 2026-05-04T23:49:29.162Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:01:31.010Z Everads Therapy Publishes First-in-Human Clinical Data for Suprachoroidal Injector in Ophthalmology Science https://novapharmanews.com/uploads/articles/everads-therapy-suprachoroidal-injector-clinical-data-ophthalmology-science.webp Everads Therapy Publishes First-in-Human Clinical Data for Suprachoroidal Injector in Ophthalmology Science https://novapharmanews.com/us/news/ucb-acquires-candid-therapeutics-autoimmune-deal 2026-05-04T23:15:17.853Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:01:05.077Z UCB Acquires Candid Therapeutics in Major Autoimmune Drug Development Deal https://novapharmanews.com/uploads/articles/ucb-acquires-candid-therapeutics-autoimmune-deal.webp UCB Acquires Candid Therapeutics in Major Autoimmune Drug Development Deal https://novapharmanews.com/us/news/spinogenix-tazbentetol-neuroprotective-glaucoma-diabetic-retinopathy-arvo-2026 2026-05-05T05:19:21.403Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:00:41.363Z Spinogenix Tazbentetol Shows Neuroprotective Effects in Glaucoma and Diabetic Retinopathy Preclinical Studies at ARVO 2026 https://novapharmanews.com/uploads/articles/spinogenix-tazbentetol-neuroprotective-glaucoma-diabetic-retinopathy-arvo-2026.webp Spinogenix Tazbentetol Shows Neuroprotective Effects in Glaucoma and Diabetic Retinopathy Preclinical Studies at ARVO 2026 https://novapharmanews.com/us/news/niktimvo-axatilimab-approved-australia-chronic-gvhd-treatment 2026-05-05T05:19:23.679Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T03:00:20.396Z NIKTIMVO (Axatilimab) Approved in Australia as First-in-Class Chronic Graft-Versus-Host Disease Treatment https://novapharmanews.com/uploads/articles/niktimvo-axatilimab-approved-australia-chronic-gvhd-treatment.webp NIKTIMVO (Axatilimab) Approved in Australia as First-in-Class Chronic Graft-Versus-Host Disease Treatment https://novapharmanews.com/us/news/ipec-annual-meeting-2026-no-pharma-news 2026-05-04T23:18:51.406Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T00:04:53.441Z IPEC Annual Meeting 2026: No Pharma News Today https://novapharmanews.com/uploads/articles/ipec-annual-meeting-2026-no-pharma-news.webp IPEC Annual Meeting 2026: No Pharma News Today https://novapharmanews.com/eu/news/swiss-biotech-day-2026-ai-oncology-microbiome 2026-05-04T23:09:41.958Z hourly 0.9 NovaPharmaNews en-GB 2026-05-04T00:03:42.558Z Swiss Biotech Day 2026: AI, Oncology, Microbiome Highlights https://novapharmanews.com/uploads/articles/swiss-biotech-day-2026-ai-oncology-microbiome.webp Swiss Biotech Day 2026: AI, Oncology, Microbiome Highlights https://novapharmanews.com/us/news/excipient-world-conference-2026-daily-roundup 2026-05-05T05:19:30.425Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T00:02:59.839Z Excipient World Conference 2026: No Pharma Breaking News https://novapharmanews.com/uploads/articles/excipient-world-conference-2026-daily-roundup.webp Excipient World Conference 2026: No Pharma Breaking News https://novapharmanews.com/us/news/aphl-2026-annual-meeting-opens-public-health-lab-focus 2026-05-04T23:57:26.844Z hourly 0.9 NovaPharmaNews en-US 2026-05-04T00:00:53.404Z APHL 2026 Annual Meeting Opens: Public Health Lab Focus https://novapharmanews.com/uploads/articles/aphl-2026-annual-meeting-opens-public-health-lab-focus.webp APHL 2026 Annual Meeting Opens: Public Health Lab Focus https://novapharmanews.com/apac/news/fda-approves-auvelity-mdd-new-antidepressant 2026-05-05T05:17:32.940Z hourly 0.9 NovaPharmaNews en 2026-05-03T07:07:55.125Z FDA Approves Auvelity for MDD: A New Antidepressant Option https://novapharmanews.com/uploads/articles/fda-approves-auvelity-mdd-new-antidepressant.webp FDA Approves Auvelity for MDD: A New Antidepressant Option https://novapharmanews.com/eu/news/purdue-pharma-dissolution-approved-opioid-crisis 2026-05-05T05:11:39.135Z hourly 0.9 NovaPharmaNews en-GB 2026-05-03T07:05:42.135Z Purdue Pharma Dissolution Approved: What It Means for Opioid Crisis https://novapharmanews.com/uploads/articles/purdue-pharma-dissolution-approved-opioid-crisis.webp Purdue Pharma Dissolution Approved: What It Means for Opioid Crisis https://novapharmanews.com/eu/news/auvelity-fda-approval-axsome-therapeutics 2026-05-05T04:57:59.282Z hourly 0.9 NovaPharmaNews en-GB 2026-05-03T07:05:33.583Z Auvelity FDA Approval: New Hope for MDD Patients https://novapharmanews.com/uploads/articles/auvelity-fda-approval-axsome-therapeutics.webp Auvelity FDA Approval: New Hope for MDD Patients https://novapharmanews.com/us/news/axsome-fda-approval-alzheimers-agitation 2026-05-05T02:12:19.109Z hourly 0.9 NovaPharmaNews en-US 2026-05-03T07:03:11.831Z Axsome FDA Approval for Alzheimer's Agitation Drug https://novapharmanews.com/uploads/articles/axsome-fda-approval-alzheimers-agitation.webp Axsome FDA Approval for Alzheimer's Agitation Drug https://novapharmanews.com/us/news/fda-approves-first-non-antipsychotic-dementia-agitation 2026-05-05T05:09:02.023Z hourly 0.9 NovaPharmaNews en-US 2026-05-03T07:03:10.612Z FDA Approves First Non-Antipsychotic for Dementia Agitation https://novapharmanews.com/uploads/articles/fda-approves-first-non-antipsychotic-dementia-agitation.webp FDA Approves First Non-Antipsychotic for Dementia Agitation